SLC5A2 and type 2 diabetes mellitus: Glucagon-like peptide 1 (GLP-1) receptor agonists, which increase insulin secretion, and SGLT2 inhibitors, which lower blood glucose levels by preventing glucose reabsorption in the kidney, both were shown to reduce cardiovascular events in patients with T2DM (156–160).